PRKDC and ovarian carcinoma: EGFR enhances DNA repair via catalytic subunit of DNA protein kinase (DNA-PKCs) and promotes oncogenic signaling via PI-3K/AKT [35].Targeting EGFR using pharmacological inhibitors such as Iressa has been postulated to improve ovarian cancer therapy outcome and Iressa responding patient population has been identified [36].